Martre H, Sari R, Taburet A M, Jacobs C, Singlas E
Br J Clin Pharmacol. 1985 Aug;20(2):155-8. doi: 10.1111/j.1365-2125.1985.tb05049.x.
To establish dosage recommendations in patients with end-stage renal disease undergoing chronic haemodialysis, nifedipine kinetics were studied between and during haemodialysis sessions. In eight patients, during the interdialytic period, peak plasma concentrations of nifedipine (29-332 ng/ml) were reached 0.5-1.0 h after administration of a single 10 mg oral dose. Elimination half-life and oral plasma clearance were respectively 2.6 +/- 0.5 h and 1 176 +/- 412 ml/min. Nifedipine plasma protein binding was decreased in uraemic patients (88.8 +/- 0.3% vs 94.4 +/- 0.1%) but not affected by haemodialysis. Removal by haemodialysis was low: the dialyser extraction ratio and the dialysis clearance were respectively 2.3 +/- 0.8% and 2.8 +/- 0.9 ml/min.
为了确定接受慢性血液透析的终末期肾病患者的用药剂量建议，研究了血液透析期间及透析间期硝苯地平的动力学。在8名患者中，透析间期单次口服10mg剂量后，硝苯地平的血浆峰值浓度（29 - 332ng/ml）在给药后0.5 - 1.0小时达到。消除半衰期和口服血浆清除率分别为2.6±0.5小时和1176±412ml/分钟。尿毒症患者硝苯地平的血浆蛋白结合率降低（88.8±0.3%对94.4±0.1%），但不受血液透析影响。血液透析清除率较低：透析器提取率和透析清除率分别为2.3±0.8%和2.8±0.9ml/分钟。
